Condition: Breast Cancer, Metastatic · Sponsor: European Institute of Oncology
Development and validation of an integrated testing strategy for simultaneous detection of ESR-1 and gBRCA mutations via liquid biopsy in HR+/HER2- metastatic breast cancer (mBC) patients, and the creation of a digital gene library to support an evidence-based diagnostic algorithm
This description comes directly from the study's public registry record.
Nicola Fusco, MD · 00390294372079 · nicola.fusco@ieo.it
francesca lombardi, biologist · 00390257489425 · francesca.lombardi@ieo.it
Always discuss trial participation with your own doctor first.
| European Institute of oncology | Milan, Italy, Italy | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06762483